Navigation Links
Research Shows 10-15% Will Need Periodontal Treatment – Act Now, Warn Eludril and Elgydium
Date:4/23/2013

Bournemouth, Dorset (PRWEB) April 23, 2013

New research which shows that 10 to 15 per cent of adults will develop periodontitis has prompted a warning from the manufacturers of Elgydium toothpaste and Eludril mouthwash.

The research – published recently in the National Library of Medicine – highlights the dangers of ignoring the early signs of gum disease (gingivitis).

If left unchecked, gingivitis can worsen and develop into periodontitis, an advanced form of gum disease which can attack bone as well as soft tissue.

Gum disease has far reaching consequences with well documented associations with more serious conditions such as cardiac and respiratory problems, diabetes, some cancers and osteoporosis – as well as dementia and premature birth.

“Gingivitis is serious enough but periodontitis is even more serious and can do lasting damage to the bones of the mouth as well as the gums,” said a spokesperson for Eludril and Elgydium.

“And yet there is no need to suffer with a painful gum condition. Gingivitis and periodontitis are both avoidable. Gum disease is easy to identify and simple to treat if caught early.

“Even if people miss the initial warning signs such as the gum swelling around the teeth, there are other indications which are hard to ignore.”

Blood on the gums can be caused by brushing teeth too vigorously but all too often it is a clear indication of gingivitis.

Gum recession – with or without bleeding – is another serious warning sign that should not be ignored, although this too can be caused by over-enthusiastic or careless brushing.

Regular checks by dental professionals are important in diagnosing the symptoms of gingivitis early – before the condition worsens and develops into periodontitis.

For decades, dentists and hygienists all over the world have recommended chlorhexidine (an important ingredient in both Elgydium and Eludril) as the gold standard treatment for gum disease.

Not only does chlorhexidine treat gingivitis and periodontitis but regular brushing with one of the Elgydium range of antibacterial toothpastes can help to prevent them.

Elgydium is strong enough to kill the bacteria that cause gum disease but can be used daily as part of a normal oral health regime.

Eludril gingivitis mouthwash should be used two or three times daily while symptoms persist. The recommended dosage of Eludril is 10 to 15 ml, diluted with warm water in the measuring cup provided. It is a quick and simple treatment for when gum disease is detected.

Eludril can also be used to disinfect dentures, using a one-in-three dilution with water. The dentures should be cleansed as normal then soaked in the Eludril dilution for around 60 minutes.

For further details about treating periodontitis with Eludril and Elgydium, please contact Chloe Rogers at Ceuta Healthcare on +44 (0)844 243 6661.

-Ends-

Notes For Editors

Eludril and Elgydium are represented in the UK by:

Ceuta Healthcare Ltd
Hill House
41 Richmond Hill
Bournemouth
Dorset
BH2 6HS
Tel: +44 (0)844 243 6661

Eludril Mouthwash is an antibacterial and analgesic solution which can be used to manage a number of oral health problems.

Its main use is to treat and prevent dental plaque formation and gum disease (gingivitis, also known as periodontitis) by preventing the build-up of bacteria.

Eludril Mouthwash can also be used to maintain oral hygiene in situations where tooth brushing is difficult, for instance, following oral surgery or in physically or mentally handicapped patients.

Eludril can also be used as a disinfectant for the cleansing of removable dentures and in the management of common mouth ulcers and oral candidiasis infections (fungus infections).

Elgydium Anti-Plaque toothpaste is specially formulated for sensitive gums and helps to prevent dental plaque and tartar build-up, the major causes of tooth decay and gum disease.

Elgydium Whitening, Sensitive and Decay Protection are also available as part of the Elgydium range of toothpastes.

Read the full story at http://www.prweb.com/releases/periodontal/treatment/prweb10646875.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Seena Magowitz Foundation donates $500,000 for TGen pancreatic cancer research
2. Researchers identify new pathway, enhancing tamoxifen to tame aggressive breast cancer
3. New research project aims to improve cancer therapies using type I interferons
4. Should kids sit less or move more? CHEO Research answers
5. The Melanoma Research Alliance Foundation supports CNIO research
6. Deficiency in p53 anti-tumor protein delays DNA repair after radiation, Moffitt researchers say
7. Latest research shows 2 items are key to decrease symptoms and prolong survival for LMC patients
8. Wayne State researchers seek calcium channels to target cancer tumors
9. Medical Device Market: Peru & Philippines New Market Research Report Available At Researchmoz.us
10. Toothpaste and Toothbrush Manufacturing in China Industry Research Report – Now Available from IBISWorld
11. Medical Robotic Systems Market - New Market Research Report Published by Transparency Market Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San Francisco ... using cutting-edge Oventus O2Vent technology. As many as 18 million Americans are estimated ... in breathing. Oral appliances can offer significant relief to about 75 percent of ...
(Date:10/12/2017)... ... 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ), one of ... innovative new design of the shoulder pad. The shoulder pad provides optimal support ... your pain while using cold therapy. By utilizing ice and water that is circulated ...
(Date:10/12/2017)... Rockville, Maryland (PRWEB) , ... October 12, 2017 ... ... a magnetic drug delivery system that we intend to develop to enable prevention ... regimens can lead to severe hearing loss, especially in pediatric patients. For cisplatin, ...
(Date:10/12/2017)... ... , ... Leading pediatric oncology experts at Children’s National Health System ... of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired by ... Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., Chief of the ...
(Date:10/12/2017)... ... October 12, 2017 , ... Health Literacy Innovations ... literacy software tool, and the Cancer Patient Education Network (CPEN), an independent professional ... announce a new strategic alliance. , As CPEN’s strategic partner, HLI will ...
Breaking Medicine News(10 mins):
(Date:9/23/2017)... Pa. , Sept. 22, 2017 Janssen ... a complete response letter from the U.S. Food and ... seeking approval of sirukumab for the treatment of moderately ... letter indicates additional clinical data are needed to further ... moderately to severely active RA. ...
(Date:9/22/2017)... 22, 2017 AVACEN Medical (AVACEN) announced that ... successfully helping those with the widespread pain associated with ... Amanda in Essex, England commented, ... hair, experiencing no sleep at all, tremendous pain, with ... cannot recommend [the AVACEN 100] enough, how this has ...
(Date:9/19/2017)... Sept. 19, 2017   ZirMed Inc ., a recognized ... announced that it has been ranked #1 by its users ... Rankings 2017 User Survey. ZirMed was recognized as the ... hospitals and medical centers over 200 beds and holds one ... technology user survey history. ...
Breaking Medicine Technology: